Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
iTeos Therapeutics (ITOS)
NASDAQ:ITOS
iTeos Therapeutics (ITOS) Stock Price & Analysis
108 Followers
ITOS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.52 - $35.64
Previous Close$13.93
Volume271.10K
Average Volume (3M)280.99K
Market Cap
$497.59M
Enterprise Value-$110.90M
Total Cash (Recent Filing)$613.16M
Total Debt (Recent Filing)$4.67M
Price to Earnings (P/E)5.5
Beta0.52
Next Earnings
May 11, 2023EPS Estimate
-$0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.54
Shares Outstanding35,720,401
10 Day Avg. Volume337,093
30 Day Avg. Volume280,987
Standard Deviation0.20
R-Squared0.15
Alpha0.00471
Financial Highlights & Ratios
Price to Book (P/B)0.73
Price to Sales (P/S)1.86
Price to Cash Flow (P/CF)1.70
P/FCF Ratio-4.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.41
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$39.67Price Target Upside200.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
iTeos Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ITOS FAQ
What was iTeos Therapeutics’s price range in the past 12 months?
iTeos Therapeutics lowest stock price was $12.52 and its highest was $35.64 in the past 12 months.
What is iTeos Therapeutics’s market cap?
Currently, no data Available
When is iTeos Therapeutics’s upcoming earnings report date?
iTeos Therapeutics’s upcoming earnings report date is May 11, 2023 which is in 41 days.
How were iTeos Therapeutics’s earnings last quarter?
iTeos Therapeutics released its earnings results on Mar 15, 2023. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.235 by $0.325.
Is iTeos Therapeutics overvalued?
According to Wall Street analysts iTeos Therapeutics’s price is currently Undervalued.
Does iTeos Therapeutics pay dividends?
iTeos Therapeutics does not currently pay dividends.
What is iTeos Therapeutics’s EPS estimate?
iTeos Therapeutics’s EPS estimate is -$0.81.
How many shares outstanding does iTeos Therapeutics have?
iTeos Therapeutics has 35,720,400 shares outstanding.
What happened to iTeos Therapeutics’s price movement after its last earnings report?
iTeos Therapeutics reported an EPS of $0.56 in its last earnings report, beating expectations of $0.235. Following the earnings report the stock price went down -1.749%.
Which hedge fund is a major shareholder of iTeos Therapeutics?
Among the largest hedge funds holding iTeos Therapeutics’s share is RA Capital Management. It holds iTeos Therapeutics’s shares valued at 86M.
---
iTeos Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.67 (200.76% Upside)
$39.67 (200.76% Upside)
Blogger Sentiment
Bullish
ITOS Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 136.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $118.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.41%
12-Months-Change
Fundamentals
Return on Equity
15.89%
Trailing 12-Months
Asset Growth
-14.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
iTeos Therapeutics
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
---
Top 5 ETFs holding ITOS
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold ITOS. The ETFs are listed according to market value of ITOS within the ETF
---
PureTech Health
―
4D Molecular Therapeutics
―
CTI BioPharma
―
POINT Biopharma Global
―
Anavex Life Sciences
―
---